AMRX · earnings call history
Amneal Q2 FY26 — Strong Performance, Raised Outlook, and Strategic Transformation
Read the briefAmneal Q1 FY26 — Kashiv BioSciences Acquisition and Strong Q1 Performance
Read the briefAmneal Pharmaceuticals Q4 FY25 — Strong Growth and Strategic Portfolio Expansion
Read the briefBrowse all US companies on the earnings-call register.